| Summary: | 碩士 === 國立成功大學 === 臨床藥學研究所 === 86 === Objective: To evaluate the efficacy and side effects of vigab
patients with pharmacoresistant partial epilepsy.Patients:
Patients with pharmacoresistant partial epilepsy treated at
epileptic clinic of National Cheng Kung University Hospital
regularly who were above 18 years old with at least once seizure
attack every four weeks for 12 weeks were recruited. Those who
had the history of psychosis, progressive neurological
disorders, known poor compliance and women planing to be pregant
were excluded. Methods: The baseline period lasted for 12 weeks
when the AED regimen remained constant. During the escalation
phase, 500 mg VGB was given daily in the first week and with an
increment of 500 mg every week up to 3g daily. Maintenance phase
at the daily dose of 3 gm continued for at least 12 week. the
patients visited epilepsy clinic every 4 weeks and presented the
seizure diary in which seizure type, seizure frequency
and any adverse event should be recorded. the change of seizure
frequency from baseline to maintenance phase wiil be calculated
and tested by t test and nonparametric test.Result: Forty-seven
patients jointed the study. One patient was withdrawn because of
psychosis during the study and one patient loss follow.
Consequently, 45 patients finished the maintenance phase of 12
weeks and 37 of them continued maintenance phase treatment phase
of 12 weeks and 37 of them continued maintenance phase treatment
to 24 weeks. In the maintenance phase of 12 week, the mean
seizure frequency reduction rate is 49%. 24 (53.4) out of
patients obtained more than 50% reduction of seizure at
of the study and 3 of them were free during this period. In the
maintenance phase of 24 weeks, 15 patients obtained reduction of
seizure frequency more than 50%, and 4 of them were seizure
free. The mean seizure frequency reduction rate was 36.9%.
Drowsiness was the most common adverse effect reported. Only 2
patients withdrawn from the study due to adverse effects.
Conclusion: This study showed VGB is effective and well
tolerated in the add-on therapy for 12 and 24 weeks among
persons with drug resistant partial epilepsy.
|
|---|
